FDA Updates Plavix Labeling to Warn Against Co-Administration with Other CYP2C19 Inhibitors
November 17, 2009
FDA Updates Plavix Labeling to Warn Against Co-Administration with Other CYP2C19 Inhibitors
This week's labeling change follows an earlier update from the agency informing healthcare providers of studies indicating poor CYP2C19 metabolizers have limited response to Plavix.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- New Label Warns Against Plavix with CYP2C19 Inhibitors, Raises Questions about Role of Mutations
November 18, 2009 / Pharmacogenomics Reporter - Dx Developers' Sales Pitch to Pharma Could be Key Factor in Marketing Some Tests
February 15, 2012 / Pharmacogenomics Reporter - Study Finds Genomic/Clinical Combo to Be Best Predictor of Complications in Stent Patients on Plavix
November 2, 2011 / Pharmacogenomics Reporter - FDA Issues Boxed Warning for CYP2C19-Linked Poor Metabolism of Plavix
March 17, 2010 / Pharmacogenomics Reporter - Study Points to Role of ABCB1 Gene Alterations in Plavix-Treated Patients' Cardiovascular AEs
March 17, 2010 / Pharmacogenomics Reporter